Plant Bioresources Division, Institute of Bioresources and Sustainable Development, Imphal, 795001, Manipur, India.
Infectious Disease Biology, Institute of Life Sciences, Bhubaneswar, 751023, Odisha, India; School of Biotechnology, Kalinga Institute of Industrial Technology, Bhubaneswar, 751024, Odisha, India.
J Ethnopharmacol. 2024 Mar 1;321:117466. doi: 10.1016/j.jep.2023.117466. Epub 2023 Nov 21.
Malaria is a major global health concern that is presently challenged by the emergence of Plasmodium falciparum (Pf) resistance to mainstay artemisinin-based combination therapies (ACTs). Hence, the discovery of novel and effective antimalarial drugs is pivotal to treating and controlling malaria. For many years, traditional plant-based herbal medicines have been employed in the treatment of various illnesses. Rotheca serrata (L.) Steane & Mabb. belongs to the Lamiaceae family that has been traditionally used to treat, cure, and prevent numerous diseases including malaria.
The present investigation sought to assess the phytoconstituents, antioxidant, cytotoxicity, antimalarial activities of Rotheca serrata extract and its fractions. The in vitro antiplasmodial activity was assessed in chloroquine-sensitive Pf3D7 and artemisinin-resistant PfCam3.I cultures, and the in vivo antimalarial activity was analyzed in Plasmodium berghei (Pb) ANKA strain-infected BALB/c mouse model.
The fresh leaves of Rotheca serrata were extracted in methanol (RsMeOH crude leaf extract). A portion of the extract was used to prepare successive solvent fractions using ethyl acetate (RsEA) and hexane (RsHex). The in vitro antiplasmodial activity was evaluated using [H]-hypoxanthine incorporation assays against Pf3D7 and PfCam3.I cultures. In vitro cytotoxicity study on HeLa, HEK-293T, and MCF-7 cell lines was carried out using MTT assay. The human red blood cells (RBCs) were used to perform the hemolysis assays. In vitro antioxidant studies and detailed phytochemical analysis were performed using GC-MS and FTIR. The four-day Rane's test was performed to evaluate the in vivo antimalarial activity against Pb ANKA strain-infected mice.
Phytochemical quantification of Rotheca serrata extract (RsMeOH) and its fractions (RsEA and RsHex) revealed that RsMeOH crude extract and RsEA fraction had higher contents of total phenol and flavonoid than RsHex fraction. The RsEA fraction showed potent in vitro antiplasmodial activity against Pf3D7 and PfCam3.I with IC values of 9.24 ± 0.52 μg/mL and 17.41 ± 0.43 μg/mL, respectively. The RsMeOH crude extract exhibited moderate antiplasmodial activity while the RsHex fraction showed the least antiplasmodial activity. The GC-MS and FTIR analysis of RsMeOH and RsEA revealed the presence of triterpenes, phenols, and hydrocarbons as major constituents. The RsMeOH crude extract was non-hemolytic and non-cytotoxic to HeLa, HEK-293T, and MCF-7 cell lines. The in vivo studies showed that a 1200 mg/kg dose of RsMeOH crude extract could significantly suppress parasitemia by ∼63% and prolong the survival of treated mice by ∼10 days. The in vivo antiplasmodial activity of RsMeOH was better than the RsEA fraction.
The findings of this study demonstrated that traditionally used herbal medicinal plants like R. serrata provide a platform for the identification and isolation of potent bioactive phytochemicals that in turn can promote the antimalarial drug research. RsMeOH crude extract and RsEA fraction showed antiplasmodial, antimalarial and antioxidant activities. Chemical fingerprinting analysis suggested the presence of bioactive phytocompounds that are known for their antimalarial effects. Further detailed investigations on RsMeOH crude extract and RsEA fraction would be needed for the identification of the entire repertoire of the active antimalarial components with potent pharmaceutical and therapeutic values.
ETHNOPHARMACOLOGICAL 相关性:疟疾是一个主要的全球健康问题,目前正受到恶性疟原虫(Pf)对基于青蒿素的联合疗法(ACTs)的耐药性的挑战。因此,发现新的有效抗疟药物对于治疗和控制疟疾至关重要。多年来,传统的植物草药已被用于治疗各种疾病。罗蒂卡·塞拉塔(L.)Steane 和 Mabb. 属于唇形科,传统上用于治疗、治愈和预防包括疟疾在内的许多疾病。
本研究旨在评估罗蒂卡·塞拉塔提取物及其馏分的植物化学成分、抗氧化、细胞毒性和抗疟活性。在氯喹敏感的 Pf3D7 和青蒿素耐药的 PfCam3.I 培养物中评估了体外抗疟活性,并在伯氏疟原虫(Pb)ANKA 株感染的 BALB/c 小鼠模型中分析了体内抗疟活性。
用甲醇(RsMeOH 粗叶提取物)提取罗蒂卡·塞拉塔的新鲜叶片。提取物的一部分用于用乙酸乙酯(RsEA)和正己烷(RsHex)制备连续溶剂馏分。使用[H]-次黄嘌呤掺入测定法评估体外抗疟活性 Pf3D7 和 PfCam3.I 培养物。使用 MTT 测定法在 HeLa、HEK-293T 和 MCF-7 细胞系上进行体外细胞毒性研究。使用溶血试验评估人红细胞(RBCs)的溶血活性。使用 GC-MS 和 FTIR 进行体外抗氧化研究和详细的植物化学分析。进行为期四天的 Rane 试验,以评估对 Pb ANKA 株感染小鼠的体内抗疟活性。
罗蒂卡·塞拉塔提取物(RsMeOH)及其馏分(RsEA 和 RsHex)的植物化学定量分析表明,RsMeOH 粗提物和 RsEA 馏分的总酚和类黄酮含量高于 RsHex 馏分。RsEA 馏分对 Pf3D7 和 PfCam3.I 具有较强的体外抗疟活性,IC 值分别为 9.24±0.52μg/mL 和 17.41±0.43μg/mL。RsMeOH 粗提物表现出中等的抗疟活性,而 RsHex 馏分表现出最低的抗疟活性。RsMeOH 和 RsEA 的 GC-MS 和 FTIR 分析表明,主要成分有三萜、酚类和碳氢化合物。RsMeOH 粗提物对 HeLa、HEK-293T 和 MCF-7 细胞系无溶血和细胞毒性。体内研究表明,RsMeOH 粗提物 1200mg/kg 剂量可显著抑制疟原虫血症约 63%,并延长治疗小鼠的存活时间约 10 天。RsMeOH 的体内抗疟活性优于 RsEA 馏分。
本研究结果表明,传统上使用的草药植物如罗蒂卡·塞拉塔为鉴定和分离具有潜在抗疟活性的有效植物化学物质提供了一个平台,而这些物质反过来又可以促进抗疟药物的研究。RsMeOH 粗提物和 RsEA 馏分具有抗疟、抗疟和抗氧化活性。化学指纹分析表明存在具有抗疟作用的生物活性植物化合物。需要进一步详细研究 RsMeOH 粗提物和 RsEA 馏分,以确定具有潜在药用和治疗价值的全部有效抗疟成分。